Rankings
▼
Calendar
CTMX Q1 2021 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$16M
-67.8% YoY
Gross Profit
$16M
100.0% margin
Operating Income
-$16M
-97.8% margin
Net Income
-$16M
-97.4% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
-2.5%
Cash Flow
Operating Cash Flow
-$30M
Free Cash Flow
-$31M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$434M
Total Liabilities
$288M
Stockholders' Equity
$146M
Cash & Equivalents
$330M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$16M
$50M
-67.8%
Gross Profit
$16M
$50M
-67.8%
Operating Income
-$16M
-$3M
-459.5%
Net Income
-$16M
$12M
-227.4%
← FY 2021
All Quarters
Q2 2021 →